Difference between revisions of "Excerpta Medica"

From Powerbase
Jump to: navigation, search
(→‎Ghost writing for American Home Products=)
(→‎Ghost writing for American Home Products)
Line 4: Line 4:
  
 
==Activities==
 
==Activities==
−
===Ghost writing for American Home Products===
+
===Ghost writing for 'fen-phen'===
−
In 1999 Excerpta Medica was named in sworn testimony in the first 'fen-phen' 'wrongful death trial'. The drug - [[Redux]] - was approved for use in April 1996, and both it and its mrror image [[]] d were removed from the market in September 1997 after being associated with heart-valve problems. According to the ''Houston Chronicle'':
+
 
 +
According to a 2004 ''Hastings Center Report'' - 'Pharma goes to the laundry' - by [[Carl Elliott]].<ref>Carle Elliott 'Pharma goes to the laundry: public relations and the business of medical education' ''The Hastings Center Report'' September 1, 2004, SECTION: Pg. 18(6) Vol. 34 No. 5 ISSN: 0093-0334</ref>
 +
 
 +
:One of the most ingenious pieces of the [[Fen-Phen]] public relations strategy was its ghostwriting scheme. In 1996 [[Wyeth]] hired [[Excerpta Medica Inc]], a New Jersey-based medical communications firm, to write ten articles for medical journals promoting obesity treatment. Wyeth paid Excerpta Medica $20,000 per article. In turn, Excerpta Medica paid prominent university researchers $1,000 to $1,500 to edit drafts of their articles and put their names on the published product. Wyeth kept each article under tight control, scrubbing drafts of any material that could damage sales. One draft article included sentences that read: "Individual case reports also suggest a link between dexfenfluramine and primary pulmonary hypertension." Wyeth had Excerpta delete it.<ref>C. Ornstein, "Maker of Diet-Drug Combo Accused to Funding Journal Articles," Dallas Morning News, May 23, 1999.</ref>
 +
 
 +
What made Excerpta Medica such an inspired choice is that it is a branch of the academic publisher, [[Reed Elsevier]] Plc., which publishes many of the world's most prestigious science journals. Excerpta Medica manages two journals itself: [[Clinical Therapeutics]] and [[Current Therapeutic Research]]. According to court documents, Excerpta Medica planned to submit most of the articles it produced to Elsevier journals. In the actual event, Excerpta managed to publish only two articles before Fen-Phen was withdrawn from the market in 1997. One appeared in Clinical Therapeutics, the other in the [[American Journal of Medicine]] (another Elsevier journal). In neither case did the authors of the articles disclose that they were paid by Excerpta Medica. So clean was the laundering operation, in fact, that many of the authors did not even realize that Wyeth was involved. [[Richard Atkinson]] of the [[University of Wisconsin]] wrote a letter to Excerpta Medica congratulating them on the thoroughness and clarity of their article. "Perhaps I can get you to write all my papers for me!" he wrote. He did have one reservation about the piece he was signing: "My only general comment is that this piece may make dexfenfluramine sound better than it really is."<ref>C. Ornstein, "Maker of Diet-Drug Combo Accused to Funding Journal Articles," Dallas Morning News, May 23, 1999. See also A. Mundy, Dispensing with the Truth (New York: St. Martin's Press, 2001), 164.</ref>
 +
 
 +
 
 +
In 1999 Excerpta Medica was named in sworn testimony in the first 'fen-phen' 'wrongful death trial'. The drug - [[Redux]] - was approved for use in April 1996, and both it and its mirror image [[Pondimin]] were removed from the market in September 1997 after being associated with heart-valve problems. According to the ''Houston Chronicle'':
 
:The company that developed the fen part of the fen-phen diet drug combination paid for ghost-written scientific papers on the drug and helped edit these papers before publication, testimony showed Tuesday. In a videotaped deposition played in the nation's first fen-phen wrongful death trial, American Home Products medical monitor [[Jo Alene Dolan]] acknowledged the company had asked that a sentence be stricken from a paper that suggested a link between the "fen" drug [[Redux]], or [[Dexfenfluramine]], to a rare and often deadly lung disease. The sentence was removed, Dolan said, and the information was "not conveyed" in the paper.
 
:The company that developed the fen part of the fen-phen diet drug combination paid for ghost-written scientific papers on the drug and helped edit these papers before publication, testimony showed Tuesday. In a videotaped deposition played in the nation's first fen-phen wrongful death trial, American Home Products medical monitor [[Jo Alene Dolan]] acknowledged the company had asked that a sentence be stricken from a paper that suggested a link between the "fen" drug [[Redux]], or [[Dexfenfluramine]], to a rare and often deadly lung disease. The sentence was removed, Dolan said, and the information was "not conveyed" in the paper.
  
Line 20: Line 28:
 
:"this may make desfen-fluramine sound better than it really is." Her videotaped deposition did not address whether any changes were made to address that concern. Fibich also asked why in one proposed paper a sentence was deleted that explained that long-term us-ers of diet drugs have a 23-fold greater risk of having primary pulmonary hypertension than the general public. Instead, American Home Products said studies estimate that every year 23 to 46 long-term diet drug us-ers out of a million would have the disease. She said the change reflected the scientific literature "more accurately."
 
:"this may make desfen-fluramine sound better than it really is." Her videotaped deposition did not address whether any changes were made to address that concern. Fibich also asked why in one proposed paper a sentence was deleted that explained that long-term us-ers of diet drugs have a 23-fold greater risk of having primary pulmonary hypertension than the general public. Instead, American Home Products said studies estimate that every year 23 to 46 long-term diet drug us-ers out of a million would have the disease. She said the change reflected the scientific literature "more accurately."
 
Smith took [[Pondimin]], a fen drug made by American Home Products approved for use in 1973. Plaintiffs' attorneys are accusing the company of intentionally underreporting the risks of Pondimin and Redux, which are believed to be similar because the two drugs are chemical mirror-images.
 
Smith took [[Pondimin]], a fen drug made by American Home Products approved for use in 1973. Plaintiffs' attorneys are accusing the company of intentionally underreporting the risks of Pondimin and Redux, which are believed to be similar because the two drugs are chemical mirror-images.
−
 
  
 
===Publishing Fake Journals===
 
===Publishing Fake Journals===

Revision as of 20:05, 25 August 2009

Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

Excerpta Medica is a 'strategic medical communications agency'. It 'partners' with its clients in the pharmaceutical and biotech industry to 'educate the global health care community'.[1] It is owned by Elsevier, part of Reed Elsevier.

History

Activities

Ghost writing for 'fen-phen'

According to a 2004 Hastings Center Report - 'Pharma goes to the laundry' - by Carl Elliott.[2]

One of the most ingenious pieces of the Fen-Phen public relations strategy was its ghostwriting scheme. In 1996 Wyeth hired Excerpta Medica Inc, a New Jersey-based medical communications firm, to write ten articles for medical journals promoting obesity treatment. Wyeth paid Excerpta Medica $20,000 per article. In turn, Excerpta Medica paid prominent university researchers $1,000 to $1,500 to edit drafts of their articles and put their names on the published product. Wyeth kept each article under tight control, scrubbing drafts of any material that could damage sales. One draft article included sentences that read: "Individual case reports also suggest a link between dexfenfluramine and primary pulmonary hypertension." Wyeth had Excerpta delete it.[3]

What made Excerpta Medica such an inspired choice is that it is a branch of the academic publisher, Reed Elsevier Plc., which publishes many of the world's most prestigious science journals. Excerpta Medica manages two journals itself: Clinical Therapeutics and Current Therapeutic Research. According to court documents, Excerpta Medica planned to submit most of the articles it produced to Elsevier journals. In the actual event, Excerpta managed to publish only two articles before Fen-Phen was withdrawn from the market in 1997. One appeared in Clinical Therapeutics, the other in the American Journal of Medicine (another Elsevier journal). In neither case did the authors of the articles disclose that they were paid by Excerpta Medica. So clean was the laundering operation, in fact, that many of the authors did not even realize that Wyeth was involved. Richard Atkinson of the University of Wisconsin wrote a letter to Excerpta Medica congratulating them on the thoroughness and clarity of their article. "Perhaps I can get you to write all my papers for me!" he wrote. He did have one reservation about the piece he was signing: "My only general comment is that this piece may make dexfenfluramine sound better than it really is."[4]


In 1999 Excerpta Medica was named in sworn testimony in the first 'fen-phen' 'wrongful death trial'. The drug - Redux - was approved for use in April 1996, and both it and its mirror image Pondimin were removed from the market in September 1997 after being associated with heart-valve problems. According to the Houston Chronicle:

The company that developed the fen part of the fen-phen diet drug combination paid for ghost-written scientific papers on the drug and helped edit these papers before publication, testimony showed Tuesday. In a videotaped deposition played in the nation's first fen-phen wrongful death trial, American Home Products medical monitor Jo Alene Dolan acknowledged the company had asked that a sentence be stricken from a paper that suggested a link between the "fen" drug Redux, or Dexfenfluramine, to a rare and often deadly lung disease. The sentence was removed, Dolan said, and the information was "not conveyed" in the paper.
The disease, primary pulmonary hypertension, led to the death of Mary Marisa Smith, 35, of Friends-wood in September 1997. Her family is suing Madison, N.J.-based American Home Products and the prescribing physician, Leo Borrell.

Plaintiffs' attorney Tommy Fibich accused the company of "buying science" to promote sales of the two types of fen drugs it made.

In her deposition, Dolan insisted that the company 'had done nothing wrong', reported the Chronicle. 'She said pharmaceutical companies often hire ghost writers to produce scientific literature targeted to various groups of physicians. She said such papers are scientifically accurate and the company has a right to review them before publica-tion "to have the appropriate areas covered as accurately as possible."'

The authors of such papers do not do original research, she said, but they do review other researchers' findings "so that it could be communicated to the audience." These papers often list as authors leaders in various fields. Dolan said the listed authors had the oppor-tunity to review the papers before publication to make sure they were accurate. She said American Home Products paid $ 20,000 apiece for such papers to Excerpta Medica, a company that researches the findings of others and hires ghost writers to summarize it. She said $ 1,500 of that goes to the listed author as an honorarium.

Fibich said the company didn't disclose that it was paying for the papers to be produced.

Dolan acknowledged that an editorial comment about one proposed article, the Chronicle reported, said

"this may make desfen-fluramine sound better than it really is." Her videotaped deposition did not address whether any changes were made to address that concern. Fibich also asked why in one proposed paper a sentence was deleted that explained that long-term us-ers of diet drugs have a 23-fold greater risk of having primary pulmonary hypertension than the general public. Instead, American Home Products said studies estimate that every year 23 to 46 long-term diet drug us-ers out of a million would have the disease. She said the change reflected the scientific literature "more accurately."

Smith took Pondimin, a fen drug made by American Home Products approved for use in 1973. Plaintiffs' attorneys are accusing the company of intentionally underreporting the risks of Pondimin and Redux, which are believed to be similar because the two drugs are chemical mirror-images.

Publishing Fake Journals

As of August 2009 the company discloses its policy on Industry sponsorship:

Content for Excerpta Medica’s Industry-Sponsored Publications is developed under the direction of an outside expert (eg, editor-in-chief, guest editor). Consistent with the Uniform Requirements and other generally accepted publication practices, Excerpta Medica distinguishes between authors and contributors. Authors are responsible for each article’s final content and are uniquely authorized to approve an article prior to its release/publication. Contributors are those individuals who helped to create the article, but who did not meet the criteria for authorship. Contributors are acknowledged in a manner that is appropriate for the publication (eg, on a Web site; on a masthead; in an acknowledgements section). Contributors may include, but are not limited to: copy editors; freelance writers; production staff; etc. The identity of the sponsor(s) for these publications is disclosed.[5]

The policy distinguishes between 'authors' and 'contributors' in a way that disguises the role of PR agencies and other ghost writers in process of publication.


Removing case studies from its website

Between 2006 and 2008 Excerpta Medica hosted case study material on its website. In July 2006 the list of case studies included:

  • How did Excerpta Medica extend the life cycle of a mature product in a crowded and evolving market?
  • How did Excerpta Medica create an online solution to strengthen a client's relationship with the medical community?
  • How did Excerpta Medica increase the awareness of an underdiagnosed, life-threatening condition and educate the medical community on the available treatment options?
  • With limited clinical support, how did Excerpta Medica establish a client’s product more prominently within its therapeutic marketplace?[6]

By 2009, with one exception, all of these case studies had been removed. The remaining case study titled 'With limited clinical support, how did Excerpta Medica establish a client’s product more prominently within its therapeutic marketplace?' was, however changed by removing the phrase 'company-sponsored journal' and replacing it with 'company-sponsored publication'. The website includes a foootnote acknowledging that 'In an earlier version of this case study, we stated that a “company-sponsored journal” was created when in fact this was a “company-sponsored publication”.'[7]

List of Fake Journals

Australasian Journal of Bone & Joint Medicine‎, Australasian Journal of General Practice, the Australasian Journal of Neurology, the Australasian Journal of Cardiology, the Australasian Journal of Clinical Pharmacy, the Australasian Journal of Cardiovascular Medicine.[8]

List of current journals (2009)

People

Mark Flanick, Vice President, Marketing & Business Development (USA) m.flanick@elsevier.com | Edward Roos, Global Managing Director e.roos@elsevier.com | Kathleen Coughlan, Marketing Director, Excerpta Medica Interactive k.coughlan@elsevier.com

Management Team Members

| David Benson, Business Controller | Amanda Horsford, Managing Director, Excerpta Medica Interactive | Mark Flanick, Vice President, Marketing & Business Development (USA) | Suzanne Hayes, Vice President, Operations | Rosa Real MD, CMPP, Director, Global Medical Communications | Brian O'Connor, US Managing Director | Erika Qualben, Manager Human Resources | Edward Roos, Global Managing Director | Jo-Ann West MSc, Publisher, Rapid Publications and Reprint Services[10]

Subsidiaries

Pracon & HealthIQ a subsidiary 'Founded in 1976, Pracon & HealthIQ provides services to pharmaceutical, biotech, and medical device companies in the areas of reimbursement assistance services, communications, and competitive intelligence.' In 2002 Parexel International Corp. 'announced the acquisition of Pracon & HealthIQ, a provider of specialized sales and marketing services based in Reston, Virginia and Orange, California.'[11]

Contact

Address:
Excerpta Medica USA
685 US-202
Bridgewater, NJ 08807
Telephone +1 908 547 2100
Fax +1 908 547 2200
Excerpta Medica EuropeRadarweg 29
1043 NX Amsterdam
Netherlands
Telephone +31 20 485 3975
Fax +31 20 485 3188 905 King Street West
Excerpta Medica Interactive
4th Floor
Toronto, ON
M6K 3G9 Canada
Telephone +1 416 955 9449
Fax +1 416 955 9666


Website:http://www.excerptamedica.com/

Resources

Screengrabs of deleted case studies

Further Reading

  • RON NISSIMOV 'Video shows how diet-drug maker paid for, edited scientific papers' The Houston Chronicle June 16, 1999, Wednesday 3 STAR EDITION SECTION: A; Pg. 28

Notes

  1. ↑ Excerpta Medica Home page, accessed 16 August 2009
  2. ↑ Carle Elliott 'Pharma goes to the laundry: public relations and the business of medical education' The Hastings Center Report September 1, 2004, SECTION: Pg. 18(6) Vol. 34 No. 5 ISSN: 0093-0334
  3. ↑ C. Ornstein, "Maker of Diet-Drug Combo Accused to Funding Journal Articles," Dallas Morning News, May 23, 1999.
  4. ↑ C. Ornstein, "Maker of Diet-Drug Combo Accused to Funding Journal Articles," Dallas Morning News, May 23, 1999. See also A. Mundy, Dispensing with the Truth (New York: St. Martin's Press, 2001), 164.
  5. ↑ Excerpta Medica Publication Policy, accessed 26 August 2009
  6. ↑ Excerpta Medica Case Studies, retrieved from the Internet Archive dated 10 July 2006 on 26 August 2009.
  7. ↑ Excerpta Medica Case Studies: With limited clinical support, how did Excerpta Medica establish a client’s product more prominently within its therapeutic marketplace?, accessed 26 August 2009
  8. ↑ Bob Grant Elsevier published 6 fake journals 07 May 2009, The Scientist, accessed 26 August 2009
  9. ↑ Excerpta Medica Publication Policy, accessed 26 August 2009
  10. ↑ Excerpta Medica How to reach us, accessed 26 August 2009
  11. ↑ 'MERGERS AND AQUISITIONS: Parexel acquires Pracon & HealthIQ', Health & Medicine Week, December 23, 2002, SECTION: EXPANDED REPORTING; Pg. 17
Retrieved from "https://powerbase.info/index.php?title=Excerpta_Medica&oldid=94503"